Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Fibrosarcoma is a rare malignant tumor.
• Developing targeted therapies is crucial for improving patient outcomes.
• Recombinant methioninase (rMETase) and eribulin are agents with potential anti-cancer activity.

Purpose of the Study:

• To investigate the synergistic effects of rMETase and eribulin on fibrosarcoma cells.
• To compare the efficacy of this combination therapy on cancer cells versus normal fibroblasts in vitro.
• To assess the impact of the combination on cellular and nuclear morphology.

Main Methods:

• In vitro experiments using HT1080 human fibrosarcoma cells and HS27 human fibroblasts.
• Treatment groups included control, eribulin alone, rMETase alone, and the combination of eribulin plus rMETase.
• Dual-color fluorescent protein expression was used to visualize cellular dynamics.

Main Results:

• The combination of eribulin and rMETase significantly reduced fibrosarcoma cell viability.
• Normal fibroblasts exhibited resistance to the combined treatment.
• The combination therapy induced greater nuclear fragmentation in cancer cells compared to other treatments.

Conclusions:

• The combination of eribulin and rMETase shows significant efficacy against fibrosarcoma cells in vitro.
• The differential effect on cancer cells versus normal fibroblasts suggests potential clinical applicability.
• This combination therapy warrants further investigation for fibrosarcoma treatment.